Variant Summary
- HGVS
- —
- Variant Type(s)
- —
- Evidence Items
- 7
Evidence Level Distribution
Level A: 1Level B: 3Level C: 3
Evidence Items
Showing CIViC evidence rows where gene = ERBB2 and variant = Overexpression.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Sensitivity/Response | Solid Tumor | Trastuzumab Deruxtecan | 5 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab Emtansine | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Pancreatic Cancer | Trastuzumab,Capecitabine | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Pancreatic Cancer | Gemcitabine,Trastuzumab | 4 |
| C | Predictive | Supports | Sensitivity/Response | Salivary Gland Cancer | Zoledronic Acid,Capecitabine,Trastuzumab | 3 |
| C | Predictive | Supports | Sensitivity/Response | Head And Neck Squamous Cell Carcinoma | Lapatinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Salivary Gland Cancer | Trastuzumab,Paclitaxel | 2 |